select a format

Single User License
USD 250 INR 16018
Site License
USD 500 INR 32035
Corporate User License
USD 750 INR 48053

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH41384D
  • |
  • Pages: 97
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

OPKO Health Inc (OPKO), formerly eXegenics Inc, is a biopharmaceutical and diagnostic company. It discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company's product portfolio includes point-of-care tests, laboratory developed tests ("LDTs"), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers products and vaccines that are used in the treatment of chronic kidney disease, Parkinson's disease, asthma, hemophilia, obesity, chronic obstructive pulmonary disease (COPD) and chemotherapy-induced nausea and vomiting, among others. The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada, Brazil and Israel. OPKO is headquartered in Miami, Florida, the US.

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

OPKO Health Inc, Pharmaceuticals & Healthcare, Deal Details 19

Partnerships 19

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 19

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 19

EirGen Pharma Enters into Agreement with Equity Pharma 20

Licensing Agreements 21

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 21

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 22

Opko Health Enters into Licensing Agreement with Pfizer 22

Opko Health Enters into Licensing Agreement with DSG 24

Opko Health Enters Into Licensing Agreement With Pharmsynthez 25

Opko Health Enters Into Licensing Agreement For Ranibizumab 26

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 26

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 27

OPKO Health Enters Into Licensing Agreement With ChromaDex 28

PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 29

Equity Offering 30

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 30

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 31

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 32

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 34

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 35

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 36

BioZone Pharma Completes Private Placement Of Shares For US$2.8 Million 38

Arno Therapeutics Completes Private Placement Of Units For US$30.7 Million 39

Farmsintez Announces Private Placement Of Shares For US$32.9 Million 41

RXi Pharma Completes Private Placement Of Shares For US$16 Million 41

Prolor Biotech Completes Public Offering Of Common Stock For US$37 Million 42

ChromaDex Completes Private Placement Of Common Stock For US$3.7 Million 43

OPKO Health Completes Exercise Of Underwriters' Over-allotment Option For US$110 Million 45

Debt Offering 46

Opko Health Completes Private Placement Of Notes Due 2033 For US$175 Million 46

Asset Transactions 48

RXi Pharma Acquires RNAi-Related Assets from Opko Health 48

Acquisition 49

OPKO Health Acquires 5.11% Stake in RXi Pharma 49

OPKO Health Acquires Transition Therapeutics for USD60 Million 50

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 51

Opko Health Acquires Bio-Reference Labs 52

OPKO Health Acquires EirGen Pharma for USD135 Million 54

Opko Health Acquires Inspiro Medical 55

Opko Health Completes Acquisition Of Laboratorio Arama 56

Opko Health To Acquire Stake In Zebra Biologics 56

Opko Health Completes Acquisition Of Prolor Biotech For Up To US$480 Million 57

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 59

BioReference Labs Acquires Hunter Labs 60

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 61

Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 62

Opko Health Completes Acquisition Of Silcon Comercio 64

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For US$40 Million 65

Opko Health Acquires Farmadiet For US$16.6 Million 66

Opko Health To Acquire 45% Stake In SciGen Israel From FDS Pharma 67

OPKO Health Completes Acquisition Of ALS Distribuidora For US$4 Million 68

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For US$25.3 Million 69

OPKO Health Completes Acquisition Of Drug Ingredients Maker FineTech For US$27.5 Million 70

OPKO Health Acquires CURNA 71

OPKO Health Inc-Key Competitors 73

Key Employees 74

Locations And Subsidiaries 75

Head Office 75

Other Locations & Subsidiaries 75

Recent Developments 77

Financial Announcements 77

May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 77

Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 78

Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results 80

Aug 08, 2016: OPKO Health Reports Improved Financial and Operating Results 82

May 09, 2016: OPKO Health Reports First Quarter Financial and Operating Results 83

Feb 29, 2016: OPKO Announces Financial and Operating Results 85

Corporate Communications 87

Dec 19, 2016: OPKO Health to be Added to the NASDAQ Biotechnology Index 87

Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories 88

Jun 13, 2016: OPKO Health Announces Move to NASDAQ Stock Market 89

Mar 15, 2016: OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories 90

Feb 29, 2016: OPKO's GeneDx Recognizes International Rare Disease Day with Donation of Free Exome Tests to Syndromes Without a Name 91

Product News 92

04/18/2016: Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 92

Product Approvals 93

Mar 22, 2017: OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 93

Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 94

Clinical Trials 95

Apr 25, 2016: Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 95

Feb 01, 2016: Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401 96

Appendix 97

Methodology 97

About GlobalData 97

Contact Us 97

Disclaimer 97

List of Figures

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

OPKO Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 19

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 19

EirGen Pharma Enters into Agreement with Equity Pharma 20

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 21

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 22

Opko Health Enters into Licensing Agreement with Pfizer 22

Opko Health Enters into Licensing Agreement with DSG 24

Opko Health Enters Into Licensing Agreement With Pharmsynthez 25

Opko Health Enters Into Licensing Agreement For Ranibizumab 26

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 26

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 27

OPKO Health Enters Into Licensing Agreement With ChromaDex 28

PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 29

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 30

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 31

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 32

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 34

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 35

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 36

BioZone Pharma Completes Private Placement Of Shares For US$2.8 Million 38

Arno Therapeutics Completes Private Placement Of Units For US$30.7 Million 39

Farmsintez Announces Private Placement Of Shares For US$32.9 Million 41

RXi Pharma Completes Private Placement Of Shares For US$16 Million 41

Prolor Biotech Completes Public Offering Of Common Stock For US$37 Million 42

ChromaDex Completes Private Placement Of Common Stock For US$3.7 Million 43

OPKO Health Completes Exercise Of Underwriters' Over-allotment Option For US$110 Million 45

Opko Health Completes Private Placement Of Notes Due 2033 For US$175 Million 46

RXi Pharma Acquires RNAi-Related Assets from Opko Health 48

OPKO Health Acquires 5.11% Stake in RXi Pharma 49

OPKO Health Acquires Transition Therapeutics for USD60 Million 50

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 51

Opko Health Acquires Bio-Reference Labs 52

OPKO Health Acquires EirGen Pharma for USD135 Million 54

Opko Health Acquires Inspiro Medical 55

Opko Health Completes Acquisition Of Laboratorio Arama 56

Opko Health To Acquire Stake In Zebra Biologics 56

Opko Health Completes Acquisition Of Prolor Biotech For Up To US$480 Million 57

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 59

BioReference Labs Acquires Hunter Labs 60

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 61

Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 62

Opko Health Completes Acquisition Of Silcon Comercio 64

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For US$40 Million 65

Opko Health Acquires Farmadiet For US$16.6 Million 66

Opko Health To Acquire 45% Stake In SciGen Israel From FDS Pharma 67

OPKO Health Completes Acquisition Of ALS Distribuidora For US$4 Million 68

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For US$25.3 Million 69

OPKO Health Completes Acquisition Of Drug Ingredients Maker FineTech For US$27.5 Million 70

OPKO Health Acquires CURNA 71

OPKO Health Inc, Key Competitors 73

OPKO Health Inc, Key Employees 74

OPKO Health Inc, Subsidiaries 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

OPKO Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com